A 60-year-old man was prescribed oral desmopressin (1-deamino-8-D-arginine vasopressin acetate trihydrate; DDAVP) for nocturnal polyuria. One week after starting to take desmopressin, he frequently felt chest pain while resting. Coronary angiography revealed no organic stenosis; however, an acetylcholine provocation test showed severe coronary spasm with ST elevation. He was diagnosed with coronary spastic angina, and we stopped the oral desmopressin and added diltiazem. While DDAVP should dilate the coronary vessels in healthy subjects, it may provoke coronary vasospasm in patients with endothelial dysfunction. We should be careful to avoid triggering coronary spasm when administering DDAVP to patients that may have potential endothelial dysfunction.
Introduction
Arginine vasopressin (AVP) is known to induce both systemic and coronary vasoconstriction mainly via the vasopressin V1 receptor (1) (2) (3) . A previous study showed that vasopressin causes decreased coronary flow via the constriction of small coronary arteries without large-sized focal spasm (4). Desmopressin (1-deamino-8-D-arginine vasopressin acetate trihydrate; DDAVP) is a synthetic analogue of arginine vasopressin used to treat central diabetes insipidus (5) or nocturnal polyuria (6) as a selective agonist for the vasopressin V2 receptor. Although DDAVP is an agonist for the vasopressin receptor, it has been considered that DDAVP does not induce coronary spasm (vasoconstriction), given its selectivity for the vasopressin V2 receptor. We report a case of coronary spastic angina induced after oral DDAVP administration.
Case Report
A 60-year-old man was admitted to our hospital complaining of chest pain at rest. Ten days prior to this admission, he was prescribed oral desmopressin acetate hydrate (MINIRINMELT OD Tablet 120 μg/day before sleeping) by a urologist at a nearby hospital for the treatment of nocturnal polyuria. After starting the administration of oral desmopressin, chest pain at rest frequently occurred, especially at night. On the day of hospital admission, he felt chest oppression at rest in succession at 2 AM, 5 AM, 6 AM, and 8 AM, and these episodes were relieved spontaneously or after sublingual administration of nitroglycerin. The patient then visited our hospital and was admitted emergently. An initial electrocardiogram (ECG) showed no significant ST-T changes (Fig. 1) , the findings for troponin-T were negative (troponin-I level was 6.5 pg/mL), and transthoracic echocardiography showed no segmental asynergy at rest. His lowdensity cholesterol level (LDL-C) was 80.8 mg/dL.
The patient was an ex-smoker and had a history of pulmonary adenocarcinoma which was cured by lung lobectomy one year prior to the admission. He also had a history of unstable angina three years prior to this admission and received percutaneous coronary intervention to the left circumflex artery with a drug-eluting stent. He had hypertension, dyslipidemia, and a smoking habit as coronary risk factors. He had been prescribed aspirin, statins, and a cal- cium channel blocker (amlodipine besilate 2.5 mg/day) before the admission.
On Day 2, we underwent coronary angiography, which revealed no organic stenosis, including in-stent restenosis. We performed the acetylcholine provocation test to investigate whether or not his chest pain was due to coronary spasm. Despite the continuous administration of an oral calcium channel blocker during the test, the administration of only 20 μg of acetylcholine chloride into the left coronary artery induced excessive spasm (Fig. 2) and total occlusion of the left anterior descending artery, with ST segment elevation in leads I, aVL, and V2-6 accompanied by reciprocal changes in leads II, III, and aVF (Fig. 3) . The intracoronary administration of nitroglycerin and nicorandil relieved the severe coronary spasm. He was diagnosed with coronary spastic angina (CSA), and we stopped the oral DDAVP and added diltiazem (200 mg/day). After that, he did not complain of any chest pain and was discharged on Day 6. He has been followed up without any recurrence of coronary artery spasm for 10 months.
Discussion
Nocturnal polyuria, defined as waking at night to pass urine (7), can occur at any age in any population, although the prevalence of the condition increases with age (8). DDAVP, a synthetic analogue of arginine vasopressin, relieves nocturnal polyuria by decreasing night-time urine production (6). DDAVP is a selective agonist for the vasopressin V2 receptor, which is one of three subtypes of vasopressin receptors. V1 receptors are found on the vascular smooth muscle of the systemic, splanchnic, renal, and coronary circulation systems. V1 receptors activate phospholipase C, which leads to an increase in intracellular calcium and vasoconstriction (9). V2 receptors are Gs protein-linked receptors located mainly on the renal basolateral membrane of the distal tubal and collecting ducts and activate adenylyl cyclase to increase the production of cyclic adenosine monophosphate (cAMP) (9). V3 receptors are found mainly in the pituitary gland and are thought to be involved in adrenocorticotropic hormone release (9).
The intra-arterial infusion of DDAVP, a selective V2 receptor agonist, was reported to cause a dose-dependent increase in the forearm blood flow (10). Several studies have also suggested the existence of extrarenal V2 receptors that may mediate a vasodilatory effect of AVP (10-13). Another study revealed that AVP caused endothelium-dependent relaxation of the canine basilar and coronary artery, whereas the removal of the endothelium caused basilar artery contraction by AVP (14). Endothelial NO synthase (eNOS) is known to be activated by several agonists, including acetylcholine, via an increase in the intracellular free calcium level and the binding of calmodulin to eNOS (15, 16). Furthermore, cAMP-increasing agents lead to an increase in eNOS activity, and protein kinase A (PKA) induces eNOS phosphorylation in cultured endothelial cells (17-19). DDAVP and other cAMP-increasing agents can activate eNOS in human endothelial cells, which accounts for DDAVP-induced vasodilation (20).
Patients with coronary spasm are known to have endothelial dysfunction of the coronary arteries (21, 22). Acetylcholine dilates the blood vessels via eNOS when the vascular endothelium is normal and contracts the blood vessels if there is endothelial detachment or injury (23). A similar phenomenon is supposed to happen when DDAVP is used for patients who have endothelial dysfunction. DDAVP induces vasodilatory effects for normal endothelium vessels but may cause vasoconstrictive effects in vessels with an endothelial disorder, especially under the acetylcholine provocation test. Since a smoking history (24) and the previous implantation of a drug-eluting stent (25) are closely associated with the endothelial dysfunction, DDAVP might provoke coronary vasoconstriction in the patient.
A few previous case reports have suggested the association of desmopressin with coronary spasm (26, 27). Angelini et al. reported typical Prinzmetal angina in a 50-year-old man receiving desmopressin for a pituitary insufficiency (26). Alcalde et al. reported a 64-year-old woman with recurrent severe acute pulmonary edema, which was induced by coronary artery spasm while receiving desmopressin for hypopituitarism (27). However, these previous studies did not mention the date when desmopressin was started and the date when symptoms were first noted. Therefore, no direct relationship between desmopressin and coronary spasm has yet been clearly demonstrated.
Our report suggests that DDAVP may provoke vasospasm of the coronary arteries via V2 receptors, which can be visu- alized by coronary angiography.
We reported a case of CSA induced by oral DDAVP administration. While DDAVP should dilate coronary vessels in healthy subjects, DDAVP may provoke coronary vasospasm in patients with endothelial dysfunction. This case suggests that the mechanism of DDAVP in endothelial dysfunction is at least partially responsible for the myocardial ischemia caused by vasopressin. Further, in clinical settings, we should be alert for the emergence of coronary spasm when administering DDAVP to patients that may have endothelial dysfunction.
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